Federal contractor · BOSTON, MA

ALDATU BIOSCIENCES, INC.

No contract obligations recorded for ALDATU BIOSCIENCES, INC. in FY2026. Since FY2017: $3M. It also received $2M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
N29WVC3UJCB9
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 0FY2017
  2. 3MFY2018
  3. 0FY2021
  4. 0FY2022
  5. 0FY2023

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for ALDATU BIOSCIENCES, INC. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

ALDATU BIOSCIENCES, INC. received $2M in federal assistance in FY2026, on 5 actions (0 new awards), +101% vs FY2025. Its largest program was 93.855 · Allergy and Infectious Diseases Research ($2M).

Assistance · FY2026
$2M
New awards
0
Actions
5
Since FY2021
$11.4M

Assistance by fiscal year

  1. 865.5KFY2021
  2. 2.8MFY2022
  3. 1.9MFY2023
  4. 2.9MFY2024
  5. 975KFY2025
  6. 2MFY2026

By type

  1. Grants$2M100%

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research$2M100%

Awarding agencies

  1. National Institutes of Health$2M100%
    Department of Health and Human Services

Largest awards

  1. PANDAA FOR UNIVERSAL, PAN-LINEAGE MOLECULAR DETECTION OF CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS - CRIMEAN-CONGO HEMORRHAGIC FEVER (CCHF) IS…$4.6M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Mar 24, 2021 – Aug 26, 2026· R44AI157650
  2. PANDAA FOR UNIVERSAL, PAN-LINEAGE MOLECULAR DETECTION OF FILOVIRUSES TO ENABLE RAPID EPIDEMIC RESPONSE. - EBOLAVIRUS [EBOV] AND…$3.8M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jul 27, 2022 – Sep 2, 2026· R44AI172551
  3. COMMERCIALIZATION OF PANDAA QDX FOR RAPID DRUG RESISTANCE GENOTYPING OF PROTEASE INHIBITOR ART FAILURES IN RESOURCE-LIMITED SETTINGS. - IN…$2.9M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 19, 2022 – Dec 9, 2025· SB1AI128974

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026.